Digestive & Intestinal Remedies (Pharmacies) - G20

  • G20
  • Revenue in the Digestives & Intestinal Remedies market is projected to reach US$11.66bn in 2024.
  • Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 2.38%, resulting in a market volume of US$12.81bn by 2028.
  • In global comparison, most revenue will be generated in China (US$3,367.00m in 2024).
  • In relation to total population figures, per person revenues of US$2.35 are generated in 2024.

Key regions: United States, South Korea, Japan, Canada, India

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Digestive & Intestinal Remedies (Pharmacies) market in G20 is experiencing significant growth due to changing customer preferences and trends in the market.

Customer preferences:
Customers in the Digestive & Intestinal Remedies (Pharmacies) market in G20 are increasingly seeking natural and organic remedies to address their digestive and intestinal health issues. This shift in preference is driven by a growing awareness of the potential side effects of traditional pharmaceutical products. Customers are also looking for products that provide long-term relief and promote overall gut health.

Trends in the market:
One of the key trends in the Digestive & Intestinal Remedies (Pharmacies) market in G20 is the rising demand for probiotics. Probiotics are live bacteria and yeasts that are beneficial for gut health. They help restore the natural balance of bacteria in the digestive system and promote healthy digestion. This trend is driven by the increasing awareness of the importance of gut health and the role of probiotics in maintaining it. Another trend in the market is the growing popularity of herbal remedies. Customers are turning to herbal remedies, such as herbal teas and supplements, to address their digestive and intestinal health issues. This trend is fueled by the perception that herbal remedies are safer and have fewer side effects compared to traditional pharmaceutical products.

Local special circumstances:
In the United States, the Digestive & Intestinal Remedies (Pharmacies) market is driven by the high prevalence of digestive disorders, such as irritable bowel syndrome and acid reflux. The aging population and the increasing adoption of unhealthy dietary habits are contributing to the rising incidence of these conditions. As a result, there is a growing demand for digestive and intestinal remedies in the country. In China, the Digestive & Intestinal Remedies (Pharmacies) market is driven by the traditional Chinese medicine (TCM) approach to healthcare. TCM emphasizes the balance of yin and yang energies in the body and the importance of maintaining a healthy digestive system. Chinese consumers prefer TCM-based remedies for digestive and intestinal health issues, such as herbal teas and supplements.

Underlying macroeconomic factors:
The growing Digestive & Intestinal Remedies (Pharmacies) market in G20 is also influenced by underlying macroeconomic factors. The increasing disposable income and improving healthcare infrastructure in emerging economies, such as India and Brazil, are driving the demand for digestive and intestinal remedies. Additionally, the rising healthcare costs in developed economies, such as the United States and Germany, are leading customers to seek affordable and effective over-the-counter remedies for their digestive and intestinal health issues. In conclusion, the Digestive & Intestinal Remedies (Pharmacies) market in G20 is growing due to changing customer preferences for natural and organic remedies, as well as the increasing demand for probiotics and herbal remedies. Local special circumstances, such as the high prevalence of digestive disorders in the United States and the traditional Chinese medicine approach in China, further contribute to the growth of the market. The underlying macroeconomic factors, including increasing disposable income and rising healthcare costs, also play a role in driving the demand for digestive and intestinal remedies.

Methodology

Data coverage:

The data encompasses B2C enterprises. Figures are based on offline and online spending by consumers, including VAT. Not included are B2B and B2G sales, or other pharmaceutical sales through hospitals or retail stores such as supermarkets.

Modeling approach:

Market sizes are determined through a bottom-up approach, building on specific predefined factors for each market market. As a basis for evaluating markets, we use industry associations, third-party studies and reports and survey results from our primary research (e.g., the Statista Global Consumer Survey). In addition, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per country, consumer healthcare spending, GDP and internet penetration. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the relevant market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. For forecasting digital trends such as the online-pharmacy sales share we use exponential trend smoothing and the s-curve method. The main drivers are healthcare expenditure per country and consumer healthcare spending.

Additional notes:

The data is modeled using current exchange rates. The impact of the COVID-19 pandemic and the Russia-Ukraine war are considered at a country-specific level. The market is updated twice a year. GCS data is reweighted for representativeness.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)